Rare Disease Drug Demand, Soros Interest Raising PlasmaTech Profile

PlasmaTech Biopharmaceuticals is enjoying a higher profile now that the business community is paying more attention to rare disease treatments, said the company's CEO Tim Miller.
Author:
Publish date:

PlasmaTech Biopharmaceuticals is enjoying a higher profile now that the business community is paying more attention to rare disease treatments, said the company's CEO Tim Miller. Miller took the top job after his company Abeona Therapeutics was acquired by PlasmaTech earlier this month. Miller said Abeona was a good fit for PlasmaTech because of the increasing demand for gene therapy products. He said the company's treatment to treat the genetic metabolism disorder Sanfilippo syndrome will start Phase 1/2 trials later this year. Finally, Miller said the decision by George Soros' fund to take a 5% stake in the company earlier this month also increased the profile of the company.